Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atopic Conjunctivitis Clear all
Completed Phase 4 Interventional Results available

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

NCT01443442
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
bepotastine besilate, 1.5%, Loteprednol etabonate
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 4 Interventional

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis

NCT05314621
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale, Saline nasal spray
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

A Study Of TL-925 For The Treatment of AC

NCT06293820
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

NCT03479307
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Phoenix, Arizona • Torrance, California • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

NCT01134328
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 16, 2026, 10:44 AM EDT
Not listed Phase 4 Interventional

Ocular Allergy Treatment Practical Impact Trial

NCT01808768
View directory record Official record
Conditions
Allergic Conjunctivitis, Rhinoconjunctivitis
Interventions
Alcaftadine
Drug
Lead sponsor
Starx Research Center, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Edison, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

NCT00836485
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2%, Artificial tears
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Not listed Phase 1 Interventional

Airway Immune Response to Allergens (Use Lay Language Here)

NCT04619017
View directory record Official record
Conditions
Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis
Interventions
Segmental allergen challenge
Biological
Lead sponsor
JOSALYN CHO
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions
Bilastine, Placebo
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT03494504
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Not listed Phase 2 Interventional

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

NCT01860664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
hydrocortisone ophthalmic ointment 0.5%, placebo
Drug
Lead sponsor
Koffler Vision Group
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
RX-10045, Vehicle for RX-10045 arm
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis

NCT03368339
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
PR013 (0.045%), PR013 (0.06%), Vehicle
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

NCT00423007
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

NCT00445874
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Ketotifen with a Contact Lens (no generic name)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
8 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Irvine, California • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

NCT03012165
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of ADX-102 Ophthalmic Drops
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Morrow, Georgia • Kansas City, Missouri • Mason, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 64 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 16, 2026, 10:44 AM EDT